BOOK
Update in Sexually Transmitted Infections, an Issue of Infectious Disease Clinics, E-Book
(2013)
Additional Information
Book Details
Abstract
This issue of the Infectious Disease Clinics is devoted to the treatment and prevention of the most common STDs – including syphilis, gonorrhea, herpes, and HPV. The articles will discuss the current research in the field such as antimicrobial resistance in treating gonorrhea and the development/trials of a genital herpes vaccine.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Update in SexuallyTransmitted Infections\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| Contents | v | ||
| Infectious Disease Clinics\rOf North America\r | viii | ||
| Preface\r | ix | ||
| Syphilis in the Modern Era | 705 | ||
| Key points | 705 | ||
| Etiology and pathogenesis | 705 | ||
| Epidemiology | 706 | ||
| Historical perspective | 707 | ||
| Clinical features | 708 | ||
| Early Syphilis | 708 | ||
| Primary syphilis | 708 | ||
| Secondary syphilis | 708 | ||
| Early latent syphilis | 709 | ||
| Late Syphilis | 711 | ||
| Tertiary syphilis | 711 | ||
| Late neurologic complications of syphilis | 711 | ||
| Cardiovascular syphilis | 713 | ||
| Gummatous (or late benign) syphilis | 713 | ||
| Congenital syphilis | 713 | ||
| Diagnosis | 713 | ||
| Primary Syphilis | 714 | ||
| Secondary Syphilis | 714 | ||
| Tertiary Syphilis | 715 | ||
| CSF Analysis: Indications and Interpretation | 715 | ||
| Congenital Syphilis | 715 | ||
| Treatment | 716 | ||
| Follow-up | 716 | ||
| Pregnancy and congenital syphilis | 718 | ||
| Public health response: management of sex partners | 718 | ||
| References | 719 | ||
| Control of Neisseria gonorrhoeae in the Era of Evolving Antimicrobial Resistance | 723 | ||
| Key points | 723 | ||
| Introduction | 723 | ||
| Epidemiology | 724 | ||
| Antimicrobial Surveillance | 724 | ||
| Evolution of antimicrobial resistance in Neisseria gonorrhoeae | 725 | ||
| Contemporary Cephalosporin Resistance | 725 | ||
| Cephalosporin Treatment Failures | 726 | ||
| Molecular Mechanisms of Resistance | 728 | ||
| Screening and diagnosis | 728 | ||
| Screening Recommendations | 728 | ||
| Diagnostic Technology | 729 | ||
| Specimen Collection | 730 | ||
| Treatment | 730 | ||
| Current Treatment Guidelines | 730 | ||
| Potential Future Treatment Options | 731 | ||
| Test-of-Cure and Rescreening | 732 | ||
| Partner Treatment | 732 | ||
| A Gonorrhea Vaccine? | 732 | ||
| Summary | 733 | ||
| References | 733 | ||
| Screening and Management of Genital Chlamydial Infections | 739 | ||
| Key points | 739 | ||
| Introduction | 739 | ||
| Clinical manifestations in women | 740 | ||
| Cervicitis | 740 | ||
| Urethritis | 740 | ||
| Pelvic inflammatory disease | 740 | ||
| Clinical manifestations in men | 741 | ||
| Urethritis | 741 | ||
| Epididymitis | 741 | ||
| Prostatitis | 742 | ||
| Proctitis/Proctocolitis | 742 | ||
| LGV | 743 | ||
| Pharyngeal Infection | 743 | ||
| Diagnosis | 743 | ||
| NAAT | 743 | ||
| Screening | 744 | ||
| Epidemiology | 744 | ||
| Young women | 745 | ||
| Race/Ethnicity | 745 | ||
| Sexual minority populations | 745 | ||
| WSW | 746 | ||
| MSM | 747 | ||
| LGV | 747 | ||
| Treatment | 748 | ||
| Follow-up | 750 | ||
| Summary | 750 | ||
| References | 751 | ||
| Trichomoniasis | 755 | ||
| Key points | 755 | ||
| Introduction | 755 | ||
| Epidemiology | 755 | ||
| Pathophysiology | 756 | ||
| Diagnosis | 757 | ||
| Clinical management | 758 | ||
| Adverse outcomes | 759 | ||
| Special considerations | 760 | ||
| HIV | 760 | ||
| Pregnancy and Breastfeeding | 760 | ||
| Children | 761 | ||
| Prevention | 761 | ||
| Controversies | 761 | ||
| Summary | 761 | ||
| References | 761 | ||
| HPV and HPV-Associated Diseases | 765 | ||
| Key points | 765 | ||
| Background | 765 | ||
| Magnitude of infection/disease burden | 766 | ||
| Epidemiology of HPV: transmission and natural history | 766 | ||
| Natural history of HPV-associated diseases | 767 | ||
| Clinical features | 768 | ||
| Screening and diagnostic approaches | 768 | ||
| Clinical management and treatment | 770 | ||
| Prevention and control | 771 | ||
| References | 775 | ||
| Mycoplasma genitalium | 779 | ||
| Key points | 779 | ||
| Introduction | 779 | ||
| M genitalium: the bacterium | 780 | ||
| M genitalium: epidemiology | 780 | ||
| Human immunodeficiency virus infection and M genitalium | 783 | ||
| Treatment | 783 | ||
| Future challenges | 784 | ||
| References | 785 | ||
| Pelvic Inflammatory Disease | 793 | ||
| Key points | 793 | ||
| Epidemiology | 793 | ||
| Etiology | 794 | ||
| Pathogenesis | 794 | ||
| Clinical evaluation and differential diagnosis | 795 | ||
| Sensitivity and specificity of CDC diagnostic criteria | 796 | ||
| Laboratory testing | 797 | ||
| Imaging studies | 797 | ||
| Inpatient versus outpatient management | 798 | ||
| CDC recommendations for antimicrobial therapy | 798 | ||
| Alternative antimicrobial regimens | 799 | ||
| Anaerobes: to cover or not? | 800 | ||
| Additional treatment considerations | 801 | ||
| Tubo-ovarian abscess | 801 | ||
| Special populations: HIV-infected women | 802 | ||
| Special populations: postmenopausal women | 802 | ||
| Special populations: intrauterine devices | 802 | ||
| Sequelae | 802 | ||
| Prevention | 803 | ||
| Summary | 803 | ||
| References | 804 | ||
| Sexual Transmission of Viral Hepatitis | 811 | ||
| Key points | 811 | ||
| Introduction | 811 | ||
| Methods | 812 | ||
| Hepatitis A | 812 | ||
| Prevention of Hepatitis A | 813 | ||
| Hepatitis B | 815 | ||
| Prevention of Hepatitis B | 817 | ||
| Hepatitis C | 820 | ||
| Sexual Transmission of HCV Among Heterosexual Partnerships | 820 | ||
| Sexual Transmission of HCV Among MSM | 820 | ||
| Prevention of Hepatitis C | 824 | ||
| Summary | 824 | ||
| References | 824 | ||
| Index | 837 |